NXTC / NextCure, Inc. - Insider Trading and Ownership Report - SEC Form 3, 4, 5

NextCure, Inc.

Deler fremragende 2,676,110 shares
Insideraktier1.601.447 shares
Insider ejerskab59,84 %
Total Insiders32
Insider-stemningsscore

Insider Sentiment Score viser, at virksomhederne bliver købt af virksomheders insidere.

Det er resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af insider-akkumulering. Scoringsmodellen bruger en kombination af nettoantallet af insidere, der har købt de foregående 90 dage, det samlede antal aktier købt som en procentdel af float og det samlede antal aktier ejet af insidere. Tallet går fra 0 til 100, hvor højere tal indikerer et højere niveau af akkumulering for sine jævnaldrende, og 50 er gennemsnittet.

Opdateringsfrekvens: Dagligt

Se Insiders Top Picks, som giver en liste over virksomheder med den højeste insider-akkumulering.

Officers sentiment score

Officer Sentiment Score finder virksomheder, der bliver købt af Corporate Officers.

Per definition er Corporate Officers Corporate Insiders, men i modsætning til nogle af de andre Insiders (10 % aktionærer og bestyrelsesmedlemmer), arbejder officerer for virksomheden på daglig basis, og de bruger deres egne penge, når de handler . (10 % aktionærer og bestyrelsesmedlemmer er ofte fondsforvaltere, der administrerer andres penge.) Som sådan er insiderhandler foretaget af embedsmænd meget mere betydningsfulde og bør behandles passende.

Ligesom Insider Sentiment Score er Officer Sentiment Score resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af officerakkumulering.

Opdateringsfrekvens: Dagligt

Se Insiders Top Picks, som giver en liste over virksomheder med højeste insider-stemning.

Nøgle Insider Metrics

Dette kort viser, hvordan virksomheden rangerer langs forskellige insider-metrics. Percentilrangen viser, hvordan denne virksomhed sammenligner sig med andre virksomheder på de amerikanske markeder. Højere placeringer er tegn på bedre situationer.

For eksempel er det generelt accepteret, at insider-køb er en positiv indikator, så virksomheder med flere insider-køb vil rangere højere end virksomheder med mindre insider-køb (eller endda insider-salg).

Netto antal insidere, der køber (rang)

0 ( )

5489 out of 11302

Netto antal insidere, der køber, er det samlede antal insiders, der køber minus det samlede antal insiders, der har solgt inden for de sidste 90 dage. Percentilrangen vises her (spænder fra 0 til 100%).

Procent af float købt af insidere (rangering)

0.000 %( )

5444 out of 11220

Procent af float købt af insidere er det samlede antal aktier købt af insidere minus det samlede antal aktier solgt af insidere inden for de sidste 90 dage, divideret med den samlede float og ganget med 100.

Insiderhandelsdiagram

NextCure, Inc. insiderhandler er vist i følgende diagram. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Generelt er det generelt ulovligt for insidere at foretage handler i deres virksomheder baseret på væsentlige, ikke-offentlige oplysninger. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4.

Insiderliste og lønsomhedsmålinger

Denne tabel viser listen over kendte insidere og genereres automatisk fra arkiveringer, der er videregivet til SEC. Ud over navnene, den seneste titel og direktør, officer eller 10 % ejerbetegnelse giver vi de seneste offentliggjorte besiddelser. Derudover giver vi, når det er muligt, den historiske handelspræstation for insideren. Den historiske handelspræstation er et vægtet gennemsnit af præstationen af faktiske købstransaktioner på det åbne marked foretaget af insideren. For mere information om, hvordan dette beregnes, se dette YouTube-webinar.

See our leaderboard of most profitable insider traders.

Insider Gennemsnitlig fortjeneste (%) Aktier
Ejet
Dele
Justeret
Alexandria Venture Investments, LLC 10% Owner - [10%] 197.993 16.499
Bingham James B. Chief Development Officer - [O] 174.262 14.522
Anne Elizabeth Borgman 10.384
Canaan X L.p. 10% Owner - [10%] 2.254.442 187.870
Canaan Partners X LLC 10% Owner - [10%] 2.254.442 187.870
Cobourn Steven P. 96.700
Ellen Feigal 10.384
James Healy 10% Owner - [10%] 2.671.856 222.655
Heller Kevin N. Chief Medical Officer - [O] 49.011 4.084
John G Houston 10.687
Insider Gennemsnitlig fortjeneste (%) Aktier
Ejet
Dele
Justeret
Elaine V Jones 14.250
David S Kabakoff Director - [D] 124.474 10.373
Chau Quang Khuong Director - [D] 2.711.013 225.918
Sourav Kundu 58.700
Sol Langermann Chief Scientific Officer - [O] 74.684 6.224
Judith Li 14.250
Linda Liu SVP, Research - [O] 55.234 4.603
Timothy Mayer 131.200
Anand Mehra 10% Owner - [10%] 2.671.856 222.655
Briggs Morrison 14.250
Han Myint 103.600
Insider Gennemsnitlig fortjeneste (%) Aktier
Ejet
Dele
Justeret
Garry A Nicholson 28.500
Orbimed Advisors Llc Director, 10% Owner - [D] [10%] 2.711.013 225.918
OrbiMed Capital GP VI LLC Director, 10% Owner - [D] [10%] 2.711.013 225.918
Michael Powell 10% Owner - [10%] 2.671.856 222.655
Michael Richman President & CEO, Director, 10% Owner - [D] [O] [10%] 771.738 64.312
Timothy M Shannon Director - [D] 2.254.442 187.870
Simcere Zaiming, Inc. 10% Owner - [10%] 338.636 338.636
Sofinnova Management IX, L.L.C. 10% Owner - [10%] 2.671.856 222.655
Sofinnova Venture Partners IX, L.P. 10% Owner - [10%] 2.671.856 222.655
Stephen W Webster 14.250
Stella Xu Director - [D] 1.103.570 91.964

Report errors via our new Insider Auditing Tool

Track Records af insiderkøb - Kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i NXTC / NextCure, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2019-11-15 Sofinnova Venture Partners IX, L.P. 150.000 36,7500 12.500 441,0000 5.512.500 38 66 -4.687.500 -85,03
2019-05-13 CANAAN X L.P. 50.000 15,0000 4.167 180,0000 750.000
2019-05-13 Sofinnova Venture Partners IX, L.P. 400.000 15,0000 33.333 180,0000 6.000.000
2019-05-13 ORBIMED ADVISORS LLC 350.000 15,0000 29.167 180,0000 5.250.000
2019-05-13 Xu Stella 125.000 15,0000 10.417 180,0000 1.875.000

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

NXTC / NextCure, Inc. Insider Trades
Track Records af insidersalg - Kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i NXTC / NextCure, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

NXTC / NextCure, Inc. Insider Trades
Transaktionshistorik

Klik på linkikonet for at se den fulde transaktionshistorik. Transaktioner, der rapporteres som en del af en automatisk handelsplan 10b5-1, vil have et X i kolonnen markeret 10b-5.

Fil
Dato
Handle
Dato
Form Insider Ticker Sikkerhedstitel Kode 10b5-1 Direkte Dyrke motion
Pris
Enhed
Pris
Enheder
Ændret
Værdi
Ændret (1K)
Tilbage
Muligheder
Tilbage
Aktier
2025-08-19 3 Simcere Zaiming, Inc. See footnotes NXTC Common Stock I 338.636
2022-02-02 2022-01-31 4 Liu Linda NXTC Employee Stock Option (Right to Buy) A - Award D 5,57 65.600 65.600
2022-02-02 2022-01-31 4 Langermann Sol NXTC Employee Stock Option (Right to Buy) A - Award D 5,57 117.400 117.400
2022-02-02 2022-01-31 4 Kundu Sourav NXTC Employee Stock Option (Right to Buy) A - Award D 5,57 58.700 58.700
2022-02-02 2022-01-31 4 Mayer Timothy NXTC Employee Stock Option (Right to Buy) A - Award D 5,57 131.200 131.200
2022-02-02 2022-01-31 4 Richman Michael NXTC Employee Stock Option (Right to Buy) A - Award D 5,57 262.400 262.400
2022-02-02 2022-01-31 4 Cobourn Steven P. NXTC Employee Stock Option (Right to Buy) A - Award D 5,57 96.700 96.700
2022-02-02 2022-01-31 4 Myint Han NXTC Employee Stock Option (Right to Buy) A - Award D 5,57 103.600 103.600
2021-10-05 2021-10-01 4 Feigal Ellen NXTC Stock Option (Right to Buy) A - Award D 7,56 10.384 10.384
2021-10-05 2021-10-01 4 Feigal Ellen NXTC Stock Option (Right to Buy) A - Award D 7,56 28.500 28.500
2021-10-05 2021-10-01 4 Borgman Anne Elizabeth NXTC Stock Option (Right to Buy) A - Award D 7,56 10.384 10.384
2021-10-05 2021-10-01 4 Borgman Anne Elizabeth NXTC Stock Option (Right to Buy) A - Award D 7,56 28.500 28.500
2021-07-19 2021-07-15 4 Kundu Sourav NXTC Employee Stock Option (Right to Buy) A - Award D 7,89 150.000 150.000
2021-06-28 2021-06-24 4 Houston John G NXTC Stock Option (Right to Buy) A - Award D 8,21 14.250 14.250
2021-06-28 2021-06-24 4 Nicholson Garry A NXTC Stock Option (Right to Buy) A - Award D 8,21 14.250 14.250
2021-06-28 2021-06-24 4 Xu Stella NXTC Stock Option (Right to Buy) A - Award D 8,21 14.250 14.250
2021-06-28 2021-06-24 4 KABAKOFF DAVID S NXTC Stock Option (Right to Buy) A - Award D 8,21 14.250 14.250
2021-06-28 2021-06-24 4 Jones Elaine V NXTC Stock Option (Right to Buy) A - Award D 8,21 14.250 14.250
2021-06-28 2021-06-24 4 Webster Stephen W NXTC Stock Option (Right to Buy) A - Award D 8,21 14.250 14.250
2021-06-28 2021-06-24 4 Khuong Chau Quang NXTC Stock Option (Right to Buy) A - Award D 8,21 14.250 14.250
2021-03-16 2021-03-15 4 Richman Michael NXTC Employee Stock Option (Right to Buy) A - Award D 12,59 300.000 300.000
2021-03-16 2021-03-15 4 Mayer Timothy NXTC Employee Stock Option (Right to Buy) A - Award D 12,59 100.000 100.000
2021-03-16 2021-03-15 4 Liu Linda NXTC Employee Stock Option (Right to Buy) A - Award D 12,59 100.000 100.000
2021-03-16 2021-03-15 4 Langermann Sol NXTC Employee Stock Option (Right to Buy) A - Award D 12,59 100.000 100.000
2021-03-16 2021-03-15 4 Cobourn Steven P. NXTC Employee Stock Option (Right to Buy) A - Award D 12,59 100.000 100.000
2021-01-19 2021-01-13 4 Myint Han NXTC Employee Stock Option (Right to Buy) A - Award D 12,09 200.000 200.000
2020-09-14 2020-09-10 4 Houston John G NXTC Stock Option (Right to Buy) A - Award D 9,14 10.687 10.687
2020-09-14 2020-09-10 4 Houston John G NXTC Stock Option (Right to Buy) A - Award D 9,14 28.500 28.500
2020-07-16 2020-07-14 4 Heller Kevin N. NXTC Employee Stock Option (Right to Buy) M - Exercise D 1,77 -27.229 38.119
2020-07-16 2020-07-14 4 Heller Kevin N. NXTC Common Stock M - Exercise D 1,7700 27.229 48 49.011
2020-06-15 2020-06-11 4 Webster Stephen W NXTC Stock Option (Right to Buy) A - Award D 24,13 14.250 14.250
2020-06-15 2020-06-11 4 Xu Stella NXTC Stock Option (Right to Buy) A - Award D 24,13 14.250 14.250
2020-06-15 2020-06-11 4 Khuong Chau Quang NXTC Stock Option (Right to Buy) A - Award D 24,13 14.250 14.250
2020-06-15 2020-06-11 4 Li Judith NXTC Stock Option (Right to Buy) A - Award D 24,13 14.250 14.250
2020-06-15 2020-06-11 4 Morrison Briggs NXTC Stock Option (Right to Buy) A - Award D 24,13 14.250 14.250
2020-06-15 2020-06-11 4 Nicholson Garry A NXTC Stock Option (Right to Buy) A - Award D 24,13 28.500 28.500
2020-06-15 2020-06-11 4 Nicholson Garry A NXTC Stock Option (Right to Buy) A - Award D 24,13 16.083 16.083
2020-06-15 2020-06-11 4 KABAKOFF DAVID S NXTC Stock Option (Right to Buy) A - Award D 24,13 14.250 14.250
2020-06-15 2020-06-11 4 Jones Elaine V NXTC Stock Option (Right to Buy) A - Award D 24,13 14.250 14.250
2020-03-03 2020-02-28 4 Richman Michael NXTC Employee Stock Option (Right to Buy) A - Award D 41,76 225.000 225.000
2020-03-03 2020-02-28 4 Mayer Timothy NXTC Employee Stock Option (Right to Buy) A - Award D 41,76 78.200 78.200
2020-03-03 2020-02-28 4 Liu Linda NXTC Employee Stock Option (Right to Buy) A - Award D 41,76 39.100 39.100
2020-03-03 2020-02-28 4 Langermann Sol NXTC Employee Stock Option (Right to Buy) A - Award D 41,76 78.200 78.200
2020-03-03 2020-02-28 4 Heller Kevin N. NXTC Employee Stock Option (Right to Buy) A - Award D 41,76 100.050 100.050
2020-03-03 2020-02-28 4 Cobourn Steven P. NXTC Employee Stock Option (Right to Buy) A - Award D 41,76 78.200 78.200
2020-03-03 2020-02-28 4 Bingham James B. NXTC Employee Stock Option (Right to Buy) A - Award D 41,76 78.200 78.200
2020-02-21 2019-11-27 4 Liu Linda NXTC Employee Stock Option (Right to Buy) M - Exercise D 1,21 -20.745 10.373
2020-02-21 2019-11-27 4 Liu Linda NXTC Employee Stock Option (Right to Buy) M - Exercise D 0,48 -34.489 9.076
2020-02-21 2019-11-27 4 Liu Linda NXTC Common Stock M - Exercise D 1,2100 20.745 25 55.234
2020-02-21 2019-11-27 4 Liu Linda NXTC Common Stock M - Exercise D 0,4800 34.489 17 34.489
2019-11-19 2019-11-15 4 Sofinnova Venture Partners IX, L.P. NXTC Common Stock P - Purchase D 36,7500 150.000 5.512 2.671.856
2019-06-17 2019-06-13 4 Li Judith NXTC Stock Option (Right to Buy) A - Award D 15,57 22.000 22.000
2019-06-17 2019-06-13 4 Khuong Chau Quang NXTC Stock Option (Right to Buy) A - Award D 15,57 22.000 22.000
2019-06-17 2019-06-13 4 KABAKOFF DAVID S NXTC Stock Option (Right to Buy) A - Award D 15,57 22.000 22.000
2019-06-17 2019-06-13 4 Jones Elaine V NXTC Stock Option (Right to Buy) A - Award D 15,57 22.000 22.000
2019-06-17 2019-06-13 4 Xu Stella NXTC Stock Option (Right to Buy) A - Award D 15,57 22.000 22.000
2019-06-17 2019-06-13 4 Webster Stephen W NXTC Stock Option (Right to Buy) A - Award D 15,57 22.000 22.000
2019-06-17 2019-06-13 4 SHANNON TIMOTHY M NXTC Stock Option (Right to Buy) A - Award D 15,57 22.000 22.000
2019-06-17 2019-06-13 4 Morrison Briggs NXTC Stock Option (Right to Buy) A - Award D 15,57 22.000 22.000
2019-05-15 2019-05-13 4 Sofinnova Venture Partners IX, L.P. NXTC Series B-1 Preferred Stock C - Conversion D -3.773.585 0
2019-05-15 2019-05-13 4 Sofinnova Venture Partners IX, L.P. NXTC Series A-3 Preferred Stock C - Conversion D -7.301.000 0
2019-05-15 2019-05-13 4 Sofinnova Venture Partners IX, L.P. NXTC Series A-2 Preferred Stock C - Conversion D -3.732.500 0
2019-05-15 2019-05-13 4 Sofinnova Venture Partners IX, L.P. NXTC Series A-1 Preferred Stock C - Conversion D -2.239.500 0
2019-05-15 2019-05-13 4 Sofinnova Venture Partners IX, L.P. NXTC Common Stock P - Purchase D 15,0000 400.000 6.000 2.521.856
2019-05-15 2019-05-13 4 Sofinnova Venture Partners IX, L.P. NXTC Common Stock C - Conversion D 469.713 2.121.856
2019-05-15 2019-05-13 4 Sofinnova Venture Partners IX, L.P. NXTC Common Stock C - Conversion D 908.785 1.652.143
2019-05-15 2019-05-13 4 Sofinnova Venture Partners IX, L.P. NXTC Common Stock C - Conversion D 464.599 743.358
2019-05-15 2019-05-13 4 Sofinnova Venture Partners IX, L.P. NXTC Common Stock C - Conversion D 278.759 278.759
2019-05-13 2019-05-13 4 ORBIMED ADVISORS LLC See footnotes NXTC Series B-1 Preferred Stock C - Conversion I -3.554.466 0
2019-05-13 2019-05-13 4 ORBIMED ADVISORS LLC See footnotes NXTC Series A-3 Preferred Stock C - Conversion I -5.861.455 0
2019-05-13 2019-05-13 4 ORBIMED ADVISORS LLC See footnotes NXTC Series A-2 Preferred Stock C - Conversion I -5.970.000 0
2019-05-13 2019-05-13 4 ORBIMED ADVISORS LLC See footnotes NXTC Series A-1 Preferred Stock C - Conversion I -3.582.000 0
2019-05-13 2019-05-13 4 ORBIMED ADVISORS LLC By OrbiMed Private Investments VI, LP NXTC Common Stock P - Purchase I 15,0000 350.000 5.250 2.711.013
2019-05-13 2019-05-13 4 ORBIMED ADVISORS LLC By OrbiMed Private Investments VI, LP NXTC Common Stock C - Conversion I 442.438 2.361.013
2019-05-13 2019-05-13 4 ORBIMED ADVISORS LLC By OrbiMed Private Investments VI, LP NXTC Common Stock C - Conversion I 729.599 1.918.575
2019-05-13 2019-05-13 4 ORBIMED ADVISORS LLC By OrbiMed Private Investments VI, LP NXTC Common Stock C - Conversion I 743.110 1.188.976
2019-05-13 2019-05-13 4 ORBIMED ADVISORS LLC By OrbiMed Private Investments VI, LP NXTC Common Stock C - Conversion I 445.866 445.866
2019-05-13 2019-05-13 4 CANAAN X L.P. NXTC Series B-1 Preferred Stock C - Conversion D -2.296.605 0
2019-05-13 2019-05-13 4 CANAAN X L.P. NXTC Series A-3 Preferred Stock C - Conversion D -5.861.455 0
2019-05-13 2019-05-13 4 CANAAN X L.P. NXTC Series A-2 Preferred Stock C - Conversion D -5.970.000 0
2019-05-13 2019-05-13 4 CANAAN X L.P. NXTC Series A-1 Preferred Stock C - Conversion D -3.582.000 0
2019-05-13 2019-05-13 4 CANAAN X L.P. NXTC Common Stock P - Purchase D 15,0000 50.000 750 2.254.442
2019-05-13 2019-05-13 4 CANAAN X L.P. NXTC Common Stock C - Conversion D 285.867 2.204.442
2019-05-13 2019-05-13 4 CANAAN X L.P. NXTC Common Stock C - Conversion D 729.599 1.918.575
2019-05-13 2019-05-13 4 CANAAN X L.P. NXTC Common Stock C - Conversion D 743.110 1.188.976
2019-05-13 2019-05-13 4 CANAAN X L.P. NXTC Common Stock C - Conversion D 445.866 445.866
2019-05-13 2019-05-13 4 Xu Stella By Quan Venture Fund II, L.P. NXTC Series B-2 Preferred Stock C - Conversion I -7.861.636 0
2019-05-13 2019-05-13 4 Xu Stella By Quan Venture Fund II, L.P. NXTC Common Stock P - Purchase I 15,0000 125.000 1.875 1.103.570
2019-05-13 2019-05-13 4 Xu Stella By Quan Venture Fund II, L.P. NXTC Common Stock C - Conversion I 978.570 978.570
2019-05-13 2019-05-13 4 Khuong Chau Quang By OrbiMed Private Investments VI, LP NXTC Series B-1 Preferred Stock C - Conversion I -3.554.466 0
2019-05-13 2019-05-13 4 Khuong Chau Quang By OrbiMed Private Investments VI, LP NXTC Series A-3 Preferred Stock C - Conversion I -5.861.455 0
2019-05-13 2019-05-13 4 Khuong Chau Quang By OrbiMed Private Investments VI, LP NXTC Series A-2 Preferred Stock C - Conversion I -5.970.000 0
2019-05-13 2019-05-13 4 Khuong Chau Quang By OrbiMed Private Investments VI, LP NXTC Series A-1 Preferred Stock C - Conversion I -3.582.000 0
2019-05-13 2019-05-13 4 Khuong Chau Quang By OrbiMed Private Investments VI, LP NXTC Common Stock P - Purchase I 15,0000 350.000 5.250 2.711.013
2019-05-13 2019-05-13 4 Khuong Chau Quang By OrbiMed Private Investments VI, LP NXTC Common Stock C - Conversion I 442.438 2.361.013
2019-05-13 2019-05-13 4 Khuong Chau Quang By OrbiMed Private Investments VI, LP NXTC Common Stock C - Conversion I 729.599 1.918.575
2019-05-13 2019-05-13 4 Khuong Chau Quang By OrbiMed Private Investments VI, LP NXTC Common Stock C - Conversion I 743.110 1.188.976
2019-05-13 2019-05-13 4 Khuong Chau Quang By OrbiMed Private Investments VI, LP NXTC Common Stock C - Conversion I 445.866 445.866
2019-05-13 2019-05-13 4 SHANNON TIMOTHY M NXTC Series B-1 Preferred Stock C - Conversion I -2.296.605 0
2019-05-13 2019-05-13 4 SHANNON TIMOTHY M NXTC Series A-3 Preferred Stock C - Conversion I -5.861.455 0
2019-05-13 2019-05-13 4 SHANNON TIMOTHY M NXTC Series A-2 Preferred Stock C - Conversion I -5.970.000 0
2019-05-13 2019-05-13 4 SHANNON TIMOTHY M NXTC Series A-1 Preferred Stock C - Conversion I -3.582.000 0
2019-05-13 2019-05-13 4 SHANNON TIMOTHY M NXTC Common Stock P - Purchase I 15,0000 50.000 750 2.254.442
2019-05-13 2019-05-13 4 SHANNON TIMOTHY M NXTC Common Stock C - Conversion I 285.867 2.204.442
2019-05-13 2019-05-13 4 SHANNON TIMOTHY M NXTC Common Stock C - Conversion I 729.599 1.918.575
2019-05-13 2019-05-13 4 SHANNON TIMOTHY M NXTC Common Stock C - Conversion I 743.110 1.188.976
2019-05-13 2019-05-13 4 SHANNON TIMOTHY M NXTC Common Stock C - Conversion I 445.866 445.866
2019-05-13 2019-05-13 4 Alexandria Venture Investments, LLC NXTC Series B-1 Preferred Stock C - Conversion D -628.931 0
2019-05-13 2019-05-13 4 Alexandria Venture Investments, LLC NXTC Series A-3 Preferred Stock C - Conversion D -365.727 0
2019-05-13 2019-05-13 4 Alexandria Venture Investments, LLC NXTC Series A-2 Preferred Stock C - Conversion D -372.500 0
2019-05-13 2019-05-13 4 Alexandria Venture Investments, LLC NXTC Series A-1 Preferred Stock C - Conversion D -223.500 0
2019-05-13 2019-05-13 4 Alexandria Venture Investments, LLC NXTC Common Stock C - Conversion D 197.993 197.993
2019-05-08 3 Richman Michael NXTC Common Stock D 771.738
2019-05-08 3 Richman Michael NXTC Common Stock D 771.738
2019-05-08 3 Richman Michael NXTC Common Stock D 771.738
2019-05-08 3 Bingham James B. NXTC Common Stock D 174.262
2019-05-08 3 Bingham James B. NXTC Common Stock D 174.262
2019-05-08 3 Bingham James B. NXTC Common Stock D 174.262
2019-05-08 3 Heller Kevin N. NXTC Common Stock D 43.564
2019-05-08 3 Heller Kevin N. NXTC Common Stock D 43.564
2019-05-08 3 Heller Kevin N. NXTC Common Stock D 43.564
2019-05-08 3 KABAKOFF DAVID S NXTC Common Stock D 124.474
2019-05-08 3 KABAKOFF DAVID S NXTC Common Stock D 124.474
2019-05-08 3 KABAKOFF DAVID S NXTC Common Stock D 124.474
2019-05-08 3 Langermann Sol NXTC Common Stock D 74.684
2019-05-08 3 Langermann Sol NXTC Common Stock D 74.684
2019-05-08 3 Langermann Sol NXTC Common Stock D 74.684
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)
Other Listings
DE:2US0
DE:2US 4,73 €
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista